Opus Genetics, Inc. has disclosed recent stock transactions involving its President, Benjamin R. Yerxa. The filings indicate that Yerxa sold a total of 33,189 shares of common stock on October 23, 2026. This event is significant as it reflects the company's ongoing management of equity and tax obligations related to executive compensation.

Background

Opus Genetics, Inc., classified under the SIC code 2834 for Pharmaceutical Preparations, operates in the life sciences sector. The company is traded on the Nasdaq under the ticker symbol IRD. As a smaller reporting company, it is categorized as a non-accelerated filer. Recent filings include a series of Form 4 submissions on October 27, 2026, which detail these stock transactions.

What the Filing Says

The SEC filing reveals that Yerxa sold 7,669 shares at an average price of $3.5514 and 25,520 shares at an average price of $3.5317. The transactions were executed to satisfy tax withholding obligations arising from the vesting and settlement of restricted stock units. The filing notes, "This transaction does not represent a discretionary trade by the Reporting Person." Following these transactions, Yerxa retains ownership of 696,437 shares.

Impact

This update may affect Opus Genetics' stakeholders, including investors and employees, as it highlights the company's approach to managing executive compensation and equity. The pharmaceutical preparations industry could also see implications, as similar companies may need to evaluate their own practices regarding insider transactions and tax obligations.

What's Next

The filing does not say what happens next.